Beta
Akkermansia muciniphila MucT (pasteurised)
supplementNext-generation probiotic for metabolic health.
Reported Benefits
Safety Evaluation and Probiotic Potency Screening of Akkermansia muciniphila Strains Isolated from Human Feces and Breast Milk.
Research team
Safety evaluation of two A. muciniphila strains (AM02 and AM06) in mice showed no acute toxicity, no treatment-related deaths, and no significant differences in blood parameters, indicating safety for short-term usage.
Akkermansia in the gastrointestinal tract - Human health modifier
Research review team
Comprehensive review documenting that viable A. muciniphila MucT administration ameliorates disease and modulates immune response toward anti-inflammatory states across multiple conditions including metabolic disorders, infections, and cancer immunotherapy response.
New insights into how Akkermansia muciniphila improves metabolic health, leading to first human safety trial
Patrice D. Cani, Willem de Vos, and team
First human safety trial of pasteurised A. muciniphila in 20 subjects with excess body weight and metabolic syndrome demonstrated safety and tolerability over three months. Pasteurised form reduced fat mass development, insulin resistance, and dyslipidemia, with effects mediated through the Amuc_1100* outer membrane protein.
Akkermansia in the gastrointestinal tract - Human health modifier
Research review team
Comprehensive review documenting that viable A. muciniphila MucT administration ameliorates disease and modulates immune response toward anti-inflammatory states across multiple conditions including metabolic disorders, infections, and cancer immunotherapy response.
New insights into how Akkermansia muciniphila improves metabolic health, leading to first human safety trial
Patrice D. Cani, Willem de Vos, and team
First human safety trial of pasteurised A. muciniphila in 20 subjects with excess body weight and metabolic syndrome demonstrated safety and tolerability over three months. Pasteurised form reduced fat mass development, insulin resistance, and dyslipidemia, with effects mediated through the Amuc_1100* outer membrane protein.
New insights into how Akkermansia muciniphila improves metabolic health, leading to first human safety trial
Patrice D. Cani, Willem de Vos, and team
First human safety trial of pasteurised A. muciniphila in 20 subjects with excess body weight and metabolic syndrome demonstrated safety and tolerability over three months. Pasteurised form reduced fat mass development, insulin resistance, and dyslipidemia, with effects mediated through the Amuc_1100* outer membrane protein.
Akkermansia in the gastrointestinal tract - Human health modifier
Research review team
Comprehensive review documenting that viable A. muciniphila MucT administration ameliorates disease and modulates immune response toward anti-inflammatory states across multiple conditions including metabolic disorders, infections, and cancer immunotherapy response.
New insights into how Akkermansia muciniphila improves metabolic health, leading to first human safety trial
Patrice D. Cani, Willem de Vos, and team
First human safety trial of pasteurised A. muciniphila in 20 subjects with excess body weight and metabolic syndrome demonstrated safety and tolerability over three months. Pasteurised form reduced fat mass development, insulin resistance, and dyslipidemia, with effects mediated through the Amuc_1100* outer membrane protein.
Akkermansia in the gastrointestinal tract - Human health modifier
Research review team
Comprehensive review documenting that viable A. muciniphila MucT administration ameliorates disease and modulates immune response toward anti-inflammatory states across multiple conditions including metabolic disorders, infections, and cancer immunotherapy response.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Related health conditions
Research showing how this habit affects specific health conditions. Always consult healthcare professionals.
May Help With
Metabolic disorder characterized by high blood sugar
New insights into how Akkermansia muciniphila improves metabolic health, leading to first human safety trial
Patrice D. Cani, Willem de Vos, and team
First human safety trial of pasteurised A. muciniphila in 20 subjects with excess body weight and metabolic syndrome demonstrated safety and tolerability over three months. Pasteurised form reduced fat mass development, insulin resistance, and dyslipidemia, with effects mediated through the Amuc_1100* outer membrane protein.
Akkermansia in the gastrointestinal tract - Human health modifier
Research review team
Comprehensive review documenting that viable A. muciniphila MucT administration ameliorates disease and modulates immune response toward anti-inflammatory states across multiple conditions including metabolic disorders, infections, and cancer immunotherapy response.
Elevated LDL cholesterol or total cholesterol levels
New insights into how Akkermansia muciniphila improves metabolic health, leading to first human safety trial
Patrice D. Cani, Willem de Vos, and team
First human safety trial of pasteurised A. muciniphila in 20 subjects with excess body weight and metabolic syndrome demonstrated safety and tolerability over three months. Pasteurised form reduced fat mass development, insulin resistance, and dyslipidemia, with effects mediated through the Amuc_1100* outer membrane protein.
Research (3 studies)
Community updates
No updates yet for this supplement.
Be the first to share your experience!